18 January 2020

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

2020-01-18T15:58:59-08:00

*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC2020-01-18T15:58:59-08:00
18 January 2020

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

2020-01-18T15:31:58-08:00

*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers2020-01-18T15:31:58-08:00
20 December 2019

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community

2019-12-20T23:07:52-08:00

*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community2019-12-20T23:07:52-08:00